Pharmafile Logo
Pharmafocus logo
Advanced Search
shutterstock_512649

New NAFTA terms put hold on Canadian drug prices

December 11, 2019
Research and Development, Sales and Marketing Canada, NAFTA, US, pharma

NAFTA members have agreed to remove a provision that would have increased protections on biologics drugs. This means Canada, despite …

News
6127243966_e9189f1099_b

Multiple sclerosis market to be worth $32.9bn in 2028

December 11, 2019
Research and Development Big Pharma, MS, MS treatement, multiple sclerosis, pharma

The multiple sclerosis (MS) market is expected to see a growth in sales, and increase from $19.8 billion in 2018 …

News
fdaoutsideweb

Correvio’s atrial fibrillation drug voted down by FDA committee over safety concerns

December 11, 2019
Research and Development, Sales and Marketing Correvio Pharma, FDA, atrial fibrillation, pharma

It has emerged that Correvio Pharma’s anti-arrhythmic therapy Brinavess was shot down by the FDA’s Cardiovascular and Renal Drugs Advisory …

News
avian_influenza__bird_flu__sign_-_geograph

27,000 chickens to be culled after UK bird flu outbreak

December 11, 2019
Research and Development Bird Flu, Chicken Flu, Swin Flu, influenza, influenza b

A chicken farm in Suffolk has been confirmed by the British government to have cases of bird flu. 27,000 birds …

News

Bristol-Myers Squibb drug boasts strong overall survival in acute myeloid leukaemia

December 11, 2019
Research and Development ASH 19, Bristol-Myers Squibb, acute myeloid leukaemia, pharma

Bristol-Myers Squibb took the opportunity at the 2019 American Society of Hematology (ASH) Annual Meeting to reveal new efficacy data …

News
china_block_001_takeda_0

Takeda commits to advancing treatments for rare bleeding disorders and cancer

December 10, 2019
Manufacturing and Production, Research and Development ASH 19, Cancer, Takeda, lymphoma, oncology

Takeda presented at the 61st American Society of Hematology (ASH) Annual Meeting, 29 company-sponsored abstracts to highlight its commitment to …

News
msd

MSD set to acquire ArQule in deal worth up to $2.7 billion

December 10, 2019
Manufacturing and Production, Medical Communications, Sales and Marketing MSD, acquisition, arqule, pharma

MSD has revealed its intention to acquire biopharma firm ArQule in a deal worth a potential total of $2.7 billion, …

News

Sanofi to move away from diabetes and cardiovascular, as company shakeup continues

December 10, 2019
Manufacturing and Production ASH 19, Sanofi, Sanofi Diabetes, Sanofi Insulin, diabetes, insulin

Sanofi has said it will stop investment and research into creating new diabetes and cardiovascular drugs, as part of the …

News
samsung_bioepis

South Korea jails executives for their role in Samsung Biologics fraud

December 10, 2019
Manufacturing and Production Samsung phones, Sanofi, Sanofi Diabetes, South Korea Healthcare System, South Korea Samsung, diabetes, inhaled insulin, insulin, south korea

Three executives of Samsung Electronics have been sentenced to jail for their role in committing fraud at its biotech affiliate …

News
janssen_latest_logo_on_sign

Janssen’s Darzalex combo shows strong overall survival benefit at ASH 2019

December 10, 2019
Manufacturing and Production, Research and Development ASH 19, Janssen, darzalex, pharma

Janssen has unveiled new Phase 3 data on the efficacy of Darzalex (daratumumab) when combined with bortezomib, melphalan and prednisone …

News

Pfizer and Sangamo’s haemophilia gene therapy shows increased factor VIII levels

December 9, 2019
Manufacturing and Production, Sales and Marketing American Society of Hematology, Pfizer, Sangamo Therapeutics, hematology

Pfizer and Sangamo Therapeutics have revealed that their investigational gene therapy, SB-525, sustained increased factor VIII (FVIII) levels in patients …

News
ebolllaaaa

Johnson & Johnson to support Rwanda’s preparations against Ebola outbreak

December 9, 2019
Sales and Marketing Ebola, Ebola Guniea, Ebola virus

Johnson & Johnson will provide up to 200,000 Ebola vaccines to the Republic of Rwanda, through its pharmaceutical subsidiary Janssen. …

News
abbvie_0

Strong four-year follow-up data revealed for AbbVie’s venetoclax combo in chronic lymphocytic leukaemia

December 9, 2019
Research and Development, Sales and Marketing ASH 2019, AbbVie, chronic lymphocytic leukaemia, pharma, venetoclax

AbbVie used the platform of the American Society of Hematology (ASH) conference to present four-year follow-up analysis data on venetoclax …

News

AstraZeneca’s trial of leukaemia drug Calquence yields positive results

December 9, 2019
Sales and Marketing AstraZeneca, Calquence, leukaemia, phase 3

AstraZeneca confirmed it had recorded positive results from its Phase 3 trial of Calquence plus obinutuzumab in leukaemia. The trial …

News

Sanofi acquires biotech firm Synthorx for $2.5 billion

December 9, 2019
Sales and Marketing Genetic Alphabet, Sanofi, acute lymphoblastic leukaemia, leukaemia

Sanofi has agreed to buy California-based biotechnology firm Synthrox, in a deal worth about $2.5 billion (£1.95 billion). Paul Hudson, …

News
shutterstock_138095450

Transactions in the pharma sector: Through the EU merger review looking-glass

December 9, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, feature, mergers & acquisitions, pharma

With mergers and acquisitions back in full swing after a period of drought, Alec Burnside (Partner) and Delphine Strohl (Associate) …

Feature
jj

J&J’s CAR-T candidate boasts 100% response rate in relapsed or refractory multiple myeloma

December 9, 2019
Research and Development, Sales and Marketing ASH 2019, CAR-T, J&J, JJ, Johnson & Johnson, pharma

Johnson & Johnson were present at the American Society of Hematology (ASH) Annual Meeting over the weekend to unveil new …

News
fda-headquarters-gty-jc-181127_hpmain_12x5_608

FDA investigating if carcinogen NDMA is in diabetes drug

December 6, 2019
Medical Communications FDA, Health Canada, MDMA, NDMA, carcinogen, diabetes

The FDA is looking into if the diabetes drug metformin has unsafe levels of a cancer-causing chemical. This comes after …

News
sage_logo

Sage Therapeutics’ depression drug falls short at Phase 3

December 6, 2019
Medical Communications, Research and Development Sage Therapeutics, major depressive disorder, pharma, trial failure

Sage Therapeutics has announced that its candidate SAGE-217 flopped in Phase 3 trials investigating its efficacy in symptom reduction for …

News
bolen-report-source

Anti-vaxx movement complicit in 140,000 global measles deaths in 2018, mostly in children

December 6, 2019
Medical Communications anti vaxx, anti-vaxx, anti-vaxxers, measles mumps polio, measls, mumps, polio, vaccinations, vaccines

Over 140,000 people died from measles last year, with most of them being children under five, according to World Health …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025